Sangamo Therapeutics, Inc.
NASDAQ:SGMOBiotechnology
+$0.00 today
- Market cap
- $70.43M
- Beta
- 1.29
- P/E (TTM)
- -0.5
- EPS (TTM)
- -$0.32
Volume 0.61M
Average 9.53M
SGMO Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Sangamo Therapeutics, Inc.NASDAQ: SGMO
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables grows, but more slowly than its trailing trend
Q1 FY2026 accounts payables of $4.94M rose 17.1% year over year, behind the +170.1% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at -40.6% a year.
Context
- Accounts payables amounted to 7.1% of revenue in FY2025, down 17.4 pp from a year earlier.
- Accounts payables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +17.1% toward the trailing-twelve-month pace of +170.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 2.79M USD
- Year-over-year change
- +119.7%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.79M | +119.7% |
| FY2024 | 2024-12-31 | (14.17M) | -353.5% |
| FY2023 | 2023-12-31 | 5.59M | -58.1% |
| FY2022 | 2022-12-31 | 13.35M | +274.2% |
| FY2021 | 2021-12-31 | (7.66M) | — |
Accounts Payables vs competitors
How SGMO compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +170.1% is the highest of 10, against a peer median of -70.4%.
- Accounts payables amounts to 10.2% of revenue for SGMO, versus a peer median of 4.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.58M USD | +55.9% | — | 425.1% | |
| LTM Mar 2026 | $6.72M USD | -188.7% | — | 12.0% | |
| LTM Mar 2026 | $3.51M USD | +170.1% | -40.6% | 10.2% | |
| LTM Mar 2026 | $3.04M USD | -297.9% | — | 3.9% | |
| LTM Mar 2026 | $662K USD | -192.7% | — | 20.9% | |
| LTM Mar 2026 | CHF 504.13K CHF | -32.5% | — | — | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $337K USD | -70.4% | +107.3% | 17.3% |
| LTM Mar 2026 | $215K USD | +111.0% | — | 0.7% | |
| LTM Mar 2026 | $133K USD | -95.3% | — | 4.5% | |
| LTM Mar 2026 | $92K USD | +109.7% | -48.0% | 0.3% | |
| FY2025 | €0 EUR | — | — | 0.0% | |
| Peer median (excluding SGMO) | — | -70.4% | +29.6% | 4.5% | |
Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (178.3M) | (192.28M) | (257.83M) | (97.94M) | (122.93M) |
| Depreciation & Amortization | 17.64M | 20.56M | 22.19M | 9.36M | 7.6M |
| Deferred Income Tax | 2.77M | 0 | (6.34M) | 0 | 0 |
| Stock-Based Compensation | 32.96M | 31.65M | 27.36M | 12.38M | 9.08M |
| Change in Working Capital | (101.9M) | (82.32M) | (164.03M) | 4.51M | (4.22M) |
| Accounts Receivables | (789K) | 2.34M | (976K) | 953K | 155K |
| Inventory | 7.66M | 0 | 0 | 0 | 0 |
| Accounts Payables | (7.66M) | 13.35M | 5.59M | (14.17M) | 2.79M |
| Other Working Capital | (101.11M) | (98M) | (168.65M) | 17.72M | (7.17M) |
| Other Non-Cash Items | (6.43M) | (1.24M) | 153.8M | 4.55M | 13.27M |
| Operating Cash Flow | (233.25M) | (223.63M) | (224.84M) | (67.14M) | (97.21M) |
| Capital Expenditures | (23.28M) | (20.17M) | (21.16M) | (267K) | (102K) |
| Acquisitions (Net) | (119K) | (79.46M) | 0 | 1.95M | 0 |
| Purchases of Investments | (338.16M) | (277.39M) | (59.55M) | 0 | 0 |
| Sales of Investments | 609.76M | 356.85M | 234.24M | 35.84M | 0 |
| Other Investing Activities | 0 | 79.46M | 0 | 0 | 0 |
| Investing Cash Flow | 248.2M | 59.29M | 153.53M | 37.52M | (102K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 27.1M | 84.87M | 15.11M | 28.99M | 74.01M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 5.76M | (209K) | (518K) | (614K) | (3.26M) |
| Financing Cash Flow | 32.86M | 84.66M | 14.59M | 28.38M | 70.75M |
| Effect of Forex Changes | (263K) | 1.25M | 1.48M | (2.05M) | 4.09M |
| Net Change in Cash | 47.54M | (78.43M) | (55.24M) | (3.29M) | (22.47M) |
| Free Cash Flow | (256.53M) | (243.8M) | (246M) | (67.41M) | (97.31M) |
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
Intrinsic Alpha fair value
Locked
Current Price
$0.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.